Clinical Trial

Pre-operative Intra-nasal Dexmedetomidine or Insulin for Prevention of Early Post-operative Cognitive Dysfunction in Patients Undergoing Elective Coronary Artery Bypass Graft.

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 4, 2026 (before its estimated May 14, 2026 completion). Its status may not reflect the trial's current state.
Summary
On pump coronary revascularization is a very common leading cause for post-operative cognitive dysfunction regarding patient age grouping and diffuse systemic inflammatory response induced by bypass machine . Many factors are incriminated as pre-operative sleep disturbance, previous history of neurocognitive dysfunction. The accumulating evidence refers to an incidence between 20-40% with majority among geriatric population. The primary pathology is still elusive and many trials are under evaluation. Neuro-inflammation, hypo perfusion, fat emboli and reperfusion injury are among the most postulative aetiologias. The corner stone in the pathology of postoperative cognitive dysfunction is abnormal sleep rhythm. Intra-nasal insulin can provide neuroprotection via providing insulin growth factor and obtund neuronal apoptosis , while dexmedetomidine can antagonize neural-degeneration via regulation of systematic inflammatory cytokines including interleukin 1β, tumor necrosis factor-α, and NF-κB, inhibiting the expressions of Toll-like receptor , and through α2 adrenoceptor-mediated anti-inflammatory pathways
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-12-18; most recent amendment 2026-04-28.
Status change: Not Yet Recruiting → Recruiting 2026-04-28
Trial Details
NCT Number NCT06741566
Lead Sponsor Minia University
Conditions Post Operative Cognitive Dysfunction
Enrollment 150 participants
Start Date 2024-12-27
Primary Completion 2026-05-14 (estimated)
Study Completion 2026-05-15 (estimated)
Updated on ClinicalTrials.gov 2026-05-04